Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, 2-Period Parallel-Arm Study to Assess the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta® in Healthy Subjects

NCT02418104 is registered in ClinicalTrials.gov with Coherus Oncology, Inc. as lead sponsor.

NCT NCT02418104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02418104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, 2-Period Parallel-Arm Study to Assess the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta® in Healthy Subjects
Lead sponsor
Coherus Oncology, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2015
Completion date
December 31, 2015
Enrollment
303 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

immunity, humoral